Business
Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting
Biohaven Ltd. (NYSE: BHVN) announced today that it will present 13 abstracts at the 2025 American Academy of Neurology (AAN) Annual Meeting, taking place from April 5 to April 9, 2025 in San Diego, California. The presentations highlight Biohaven's innovative neuroscience pipeline across multiple early and late-stage development programs including Kv7 ion channel modulation, extracellular protein degradation, TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation.
About this update from Biohaven Ltd.
[{"type":"text","content":"SAN DIEGO and NEW HAVEN, Conn., April 5, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) announced today that it will present 13 abstracts at the 2025 American Academy of Neurology (AAN) Annual Meeting, taking place from April 5 to April 9, 2025 in San Diego, California. The presentations highlight Biohaven's innovative neuroscience pipeline across multiple early and late-stage development programs including Kv7 ion channel modulation, extracellular protein degradation, TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation.","length":554,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/BIOHAVEN LTD)","displaySize":"","headline":null,"caption":"(PRNewsfoto/BIOHAVEN LTD)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":117,"url":"https://media.zenfs.com/en/prnewswire.com/97c920f549c08730efa2caa3d86a161a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Pz2qjnW6oyUFys8jmleFOw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIwNjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/97c920f549c08730efa2caa3d86a161a","width":400,"height":117}},"href":"https://mma.prnewswire.com/media/1912969/Biohaven_Full_Color_rgb_2022SEPT03_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Irfan Qureshi, M.D., Chief Medical Officer of Biohaven, commented, "We are excited to highlight our clinical and scientific progress at the AAN Annual Meeting, including 3 oral presentations and 10 poster presentations, emphasizing Biohaven's innovation, leadership and commitment to developing potential first-in-class therapies for debilitating neurological disorders with inadequate or no treatment options. The team at Biohaven has been working urgently to advance our next-generation medicines as we aim to transform the way these diseases are treated. We look forward to achieving critical value-creating milestones throughout 2025 as we advance these assets across multiple high unmet need indications."","length":724,"tagName":"p"},{"type":"text","content":"The complete list of Biohaven's accepted abstracts is below. Full abstracts can be viewed online at https://index.mirasmart.com/AAN2025/.","length":141,"tagName":"p"},{"type":"text","content":"Oral Presentations:","length":19,"tagName":"p"},{"type":"text","content":"BHV-8000, a Selective Brain-penetrant TYK2/JAK1 Inhibi...